Vaginal Microbiota Among Postmenopausal Women
This study has been completed.
Sponsor:
Lawson Health Research Institute
Information provided by:
Lawson Health Research Institute
ClinicalTrials.gov Identifier:
NCT01084616
First received: March 9, 2010
Last updated: December 16, 2010
Last verified: December 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
It is known that vaginal bacteria have an impact upon the health status of the host, in some cases protecting against infection and in other cases causing infection, depending on the bacterial types present. This study will compare the composition of vaginal bacteria to symptoms of vaginal dryness in order to try and identify if certain bacteria might cause some of the problems associated with vaginal dryness among post-menopausal women.
| Condition |
|---|
|
Vulvovaginal Atrophy |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | The Role of Vaginal Microbiota in Symptoms of Vaginal Dryness in Postmenopausal Women |
Further study details as provided by Lawson Health Research Institute:
| Enrollment: | 16 |
| Study Start Date: | January 2010 |
| Study Completion Date: | July 2010 |
| Primary Completion Date: | July 2010 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
| Vaginal Dryness |
| Non-vaginal dryness |
Eligibility| Ages Eligible for Study: | 30 Years to 80 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Study Population
Postmenopausal women
Criteria
Inclusion Criteria:
- Between 30 and 80 years old.
- Postmenopausal = 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/ml or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy.
- Prepared not to take hormone replacement therapy during 8 weeks follow-up and not taking estrogen alone or estrogen/progestin containing drug products at the time of screening.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01084616
Locations
| Canada, Ontario | |
| Victoria Family Medical Center | |
| London, Ontario, Canada, ON N5Z | |
Sponsors and Collaborators
Lawson Health Research Institute
Investigators
| Principal Investigator: | Gregor Reid, PhD | Lawson Health Research Institute |
More Information
No publications provided
| Responsible Party: | Dr. Gregor Reid, Lawson Health Research Institute |
| ClinicalTrials.gov Identifier: | NCT01084616 History of Changes |
| Other Study ID Numbers: | R-09-804, 16182E |
| Study First Received: | March 9, 2010 |
| Last Updated: | December 16, 2010 |
| Health Authority: | Canada: Ethics Review Committee |
Additional relevant MeSH terms:
|
Atrophy Pathological Conditions, Anatomical |
ClinicalTrials.gov processed this record on May 16, 2013